Kenya’s Pharmaceutical Industry: Building East Africa’s Medicine Supply Chain

The case for local pharmaceutical manufacturing

The COVID-19 pandemic made visible what public health experts had been arguing for years: Africa’s dependence on imported pharmaceuticals creates a structural vulnerability that becomes critical precisely when global supply chains are under the greatest stress. When manufacturing capacity in India and China — which supply the majority of finished medicines and active pharmaceutical ingredients consumed across the continent — was disrupted by the pandemic, the consequences for African health systems were immediate and serious.

Kenya is better positioned than most African countries to respond to this challenge. Its pharmaceutical manufacturing sector, while covering only a fraction of the country’s total medicine consumption, is the most developed in East Africa and among the most significant on the continent. Kenyan manufacturers supply not only the domestic market but regional markets across Uganda, Tanzania, Rwanda, Ethiopia and beyond, making Kenya’s pharmaceutical capacity a regional asset rather than simply a national one.

The logic for strengthening this capacity is not only about pandemic preparedness. Local manufacturing creates employment, builds technical skills, reduces foreign exchange expenditure on medicine imports and — when it works well — can improve the security and reliability of medicine supply in ways that dependence on distant manufacturers cannot guarantee. The question of whether Kenya’s pharmaceutical sector can grow to meet a significantly larger share of regional medicine needs is one of the most consequential healthcare policy questions facing East Africa.

What Kenya makes and where it goes

Kenya’s pharmaceutical manufacturing base consists of approximately forty to fifty licensed manufacturers, ranging from large established companies that have been producing for decades to newer entrants whose capacity is more limited. The products manufactured span a range that reflects both the disease burden of the region and the technical capabilities of the manufacturing base: oral solid dosage forms — tablets and capsules — are the dominant product category, alongside liquid medicines, topical preparations and, more recently, some injectables.

The leading Kenyan pharmaceutical companies — Cosmos Limited, Beta Healthcare International, Regal Pharmaceuticals, Universal Corporation and others — produce generic versions of essential medicines whose patents have expired, making them available to health systems and patients at prices significantly below the branded originator versions. The public health value of high-quality generics in a market where medicine affordability is a genuine barrier to treatment cannot be overstated: the difference between a medicine that costs KSh 20 and one that costs KSh 200 determines whether patients in the lower income brackets complete their treatment courses or discontinue due to cost.

Export markets for Kenyan pharmaceuticals extend across East and Central Africa and in some cases reach West Africa and beyond. The East African Community’s regulatory harmonisation efforts — the East African Community Medicines Registration Harmonisation initiative — have simplified the multi-country approval processes that previously made regional pharmaceutical trade administratively burdensome, opening larger markets to manufacturers who invest in the regional registration processes.

Regulatory oversight and quality assurance

The Pharmacy and Poisons Board — recently rebranded as the Pharmacy and Poisons Board under new pharmaceutical legislation — is Kenya’s national medicines regulatory authority, responsible for the registration of medicines, licensing of manufacturers and distributors, and oversight of the quality, safety and efficacy of medicines in the Kenyan market.

The quality of pharmaceutical regulation in Kenya has improved significantly over the past two decades, driven partly by international support from organisations like the United States Pharmacopeia and the WHO’s prequalification programme, which has certified several Kenyan manufacturers as meeting international quality standards. WHO prequalification is significant because it allows Kenyan manufacturers to supply medicines to major international procurement programmes — UNICEF, PEPFAR, the Global Fund — that require prequalified suppliers, opening large and stable market segments that would otherwise be inaccessible.

The persistent challenge is counterfeit and substandard medicines entering the market through informal distribution channels. Kenya’s open economy and significant informal trade across its borders with Tanzania, Uganda and Ethiopia create pathways for medicines of uncertain provenance to reach patients and healthcare facilities. The PPB’s post-market surveillance activities, though resource-constrained, identify and remove substandard products from the market regularly — a reminder that regulatory compliance is not a one-time certification but an ongoing operational requirement.

Access to medicines: the distribution challenge

Manufacturing quality medicines is necessary but not sufficient to improve health outcomes. The medicines must also reach patients who need them, in appropriate quantities, at prices they can afford. Kenya’s medicine distribution system — a mix of public sector supply chains managed through the Kenya Medical Supplies Authority (KEMSA) and private sector distribution through wholesale and retail pharmacy networks — has historically been characterised by stock-outs in public facilities that leave patients without essential medicines despite adequate national supply.

KEMSA’s supply chain has been the subject of significant reform efforts, technology investments and, most controversially, high-profile corruption investigations that revealed the scale of diversion and waste in public medicine procurement. The reforms following these scandals have improved traceability and accountability in ways that are measurable, though the underlying structural challenges of last-mile distribution in a country with significant rural geography remain unresolved.

Digital tools have transformed aspects of the distribution system in ways that manual systems could not achieve. Real-time inventory tracking, mobile-based order management for health facility procurement and digital payment systems have reduced some of the friction points that previously caused supply disruptions. Mobile health information platforms that provide Kenyan patients and healthcare workers with drug information, interaction checkers and treatment guidelines sit alongside general digital services like 1win in the information ecosystem that Kenyans navigate daily on the same devices — a broader digital integration that shapes health-seeking behaviour and treatment compliance in ways that are difficult to measure but genuinely significant.

The investment case for pharmaceutical manufacturing

What Kenya offers investors

For pharmaceutical companies considering manufacturing investment in Africa, Kenya offers a combination of advantages that few alternatives can match. The skilled workforce — with significant numbers of qualified pharmacists, pharmaceutical technologists and production engineers — reduces the human capital risk that greenfield manufacturing investment in less developed markets carries. The regulatory framework, while not without challenges, is more predictable and more technically competent than in most regional comparators. The logistics infrastructure of Nairobi — the Mombasa port connection, the SGR rail link, the Jomo Kenyatta International Airport — provides connectivity to regional markets that landlocked alternatives cannot offer.

The constraints that limit growth

Against these advantages sit constraints that have limited the pharmaceutical manufacturing sector’s growth below its potential. The cost of electricity — both its price and its intermittent availability before the recent improvements in generation capacity — increases production costs for energy-intensive pharmaceutical manufacturing processes. Access to financing for capital investment in manufacturing facilities remains difficult, with lending rates and collateral requirements that disadvantage manufacturing investment relative to less capital-intensive business models. And the regulatory pathway for new product registration, while improved, remains slow enough to reduce the speed at which manufacturers can respond to emerging market opportunities.

The regional ambition

Kenya’s pharmaceutical sector has the foundation to become the manufacturing hub that serves the East African market with a substantially higher share of locally produced medicines than currently — reducing dependence on imports, building technical capabilities and creating the kind of manufacturing employment that translates science education into productive careers within the region.

Achieving this ambition requires sustained investment, continued regulatory improvement and the political will to implement the trade policies that protect and develop the regional manufacturing base without insulating it from the quality competition that drives continuous improvement. The ingredients are present. The question is whether they will be combined with the consistency that transforms a promising sector into a genuinely strategic one.